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Patient: An 18-year-old male with Autism Spectrum Disorder (ASD) and Tactile 
Defensiveness suffered a traumatic brain injury (TBI).    
 
Case Description: Pre-TBI, the patient exhibited mild tactile defensiveness but was 
independent in self-care. Two years post-TBI, he was severely spastic and completely 
dependent on others for care. His tactile defensiveness was exacerbated and his social 
and language skills were markedly diminished. He underwent a trial of intrathecal 
baclofen, followed by treatment for his spasticity with a surgical implantation of an 
intrathecal pump for continuous infusion of baclofen.   
 
Assessment/Results: Subsequent to intrathecal baclofen treatment, the patient 
showed significant reduction in his spasticity, with increased mobility and self-care. 
Unexpectedly, he demonstrated marked improvements in his tactile defensiveness and 
ASD, including social interaction skills and language ability.  
 
Discussion: Baclofen is an anti-spastic agent which is an analogue of the 
neurotransmitter gamma-amino butyric acid (GABA). Current literature describes a 
decrease in the number of GABAergic Purkinje cells, reduced levels of GABA
 
receptors, and decreased GABA synthesizing enzymes in brains of patients with 
ASD. Disruption of the GABAergic system might potentially provide a mechanism of 
action by which intrathecal baclofen (a GABA analogue) could improve symptoms of 
ASD. Further, the anti-nociceptive effect of baclofen may be the mechanism by 
which baclofen could improve symptoms of tactile defensiveness.  
 
Conclusion: This is the first reported case, to our knowledge, of treatment for tactile 
defensiveness or ASD symptoms with intrathecal baclofen. Due to the improvements 
in this patient’s tactile defensiveness, social interaction, and language ability, further 
studies are recommended. 
 
